期刊文献+

微生物来源抗肿瘤活性化合物SIPI-100-2的研究 被引量:4

Studies on the Anti-tumor Agent SIPI-100-2 from a Microorganism
下载PDF
导出
摘要 目的:分离链霉菌SIPI100菌株生物合成的具有抗肿瘤活性的化合物。方法:优化发酵条件,进行大规模发酵;发酵液经离心、乙酸乙酯萃取、硅胶柱层析等处理,从发酵液中分离出化合物SIPI1002,并测定化合物的图谱数据和生物学活性。结果:通过理化性质、质谱、紫外、红外和核磁共振等图谱数据的分析,确定化合物SIPI1002的化学结构;生物学研究发现其具有中等强度的抗肿瘤活性。结论:链霉菌SIPI100产生的活性化合物SIPI1002属于安莎类抗生素,与文献报道的17Odemethylgeldanamycin结构一致。 AIM: To isolate anti-tumor agents from Streptomyces hygroscopicus R-100. METHODS: The fermentation technology of Streptomyces hygroscopicus R-100 was further improved and the broth was obtained in a large volume; using ethyl acetate extraction, silica gel column chromatography, erystallization etc., compound SIPI-100-2 was isolated from its broth; the spectra data of SIPI-100-2 were determined and its biological activity was studied. RESULTS: By the analyses of its physico-chemical properties, MS, UV, IR and NMR spectra data, the structure of SIPI-100-2 was identified; the study on the biological activity of SIPI-100-2 found that it had moderate anti- tumor activity. CONCLUSION: SIPI-100-2 produced by Streptomyces hygroscopicus R-100 is identical with 17-O-demethylgeldanamyein and its new anti-tumor activity is found for the first time.
出处 《中国天然药物》 SCIE CAS CSCD 2006年第1期70-72,共3页
基金 上海医药工业研究院新药基金资助项目~~
关键词 抗肿瘤 安莎类抗生素 链霉菌 Anti-tumor Ansamycin Streptomyces
  • 相关文献

参考文献4

二级参考文献42

  • 11,Georgoulias, Crown JP.Increasing options in cancer therapy: current status and future prospects. Anti CancerDrugs, 1999,10(Suppl 1)∶S1
  • 22,Christian MC, Pluda JM, Ho PTC, et al. Promising new agents under development by thedivision of cancer treatment, diagnosis and centers of the national cancer institute.Semin Oncol, 1997, 24∶219
  • 33,Kollmannsberger C, Mross K, Jakob A, et al. Topotecan—a novel topoisomerase Iinhibitor: pharmacology and clinical experience. Oncology, 1999,56∶1
  • 44,Armand JP, Cunningham D, Cutsem E, et al. Clinical advances with topoisomerase Iinhibitors in gastrointestinal malignancies. Anti Cancer Drugs, 1999, 10(Suppl 12)∶S5
  • 55,Sandler A, Oosterom AT. Irinotecan in cancer of the lung and cervix. Anti CancerDrugs, 1999, 10(Suppl 1)∶S13
  • 66,Redinbo MR, Stewart L, Kuhn P, et al. Crystal structure of human topoisomerase I incovalent and noncovalent complexes with DNA. Science, 1998,279∶1504
  • 77,Stewart L, Redinbo MR, Qiu X, et al. A model for the mechanism of human topoisomeraseI. Science, 1998,279∶1534
  • 88,Kraus-Berthier L, Guilband N, Jan M, et al. Experimental antitumor activity ofS-16020-2 in a panel of human tumors. Eur J Cancer, 1997,33∶1881
  • 99,Guilbaud N, Kraus-Berthier L, Saint-Dizier D, et al. In vivo antitumor activity ofs-16020-2, a new olivacine derivative. Cancer Chemother Pharmacol, 1996, 38∶513
  • 1010,Lemee S, Pierre A, Markovits J, et al. S-16020-2, a new highly cytotoxic antitumorolivacine derivative: DNA interaction and DNA topoisomerase II inhibition. Mol Pharmacol,1998, 53∶213

共引文献40

同被引文献22

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部